👇Unfortunately sunitinib, pazopanib and cabozantinib are ineffective against #RenalMedullaryCarcinoma and need to be taken off this chart as they will produce toxicity without benefit. More info here: rmcalliance.org/treatment-info… Laurence Albiges Kidney Cancer RMC Alliance Chris Johnson Foundation Inc.

Ab#4512 ASCO #ASCO24 by #SahilDoshi👉tinyurl.com/448t2yym 👉Analysis of outcomes w/ 1L systemic Rx in chromophobe mRCC #kidneycancer👉 targeted doublet regimens ⬆️ TTF and OS compared to monotherapies 👇Martin Voss OncoAlert UroToday.com Kidney Cancer KidneyCAN

🚨 Join us during #ASCO24 🚨 Join Dr. Pal on 6/02 for an insightful live In-Person & Virtual #MedEd Symposium with @KCCure during #ASCO24! Explore the latest in #RCC treatment and get expert guidance on navigating state-of-the-art care. 🔗 bit.ly/2024RCCT

Should we change the terminology? share your views! Hope patients will chime in!

immensely 🙏for the opportunity to contribute to the development of world-class translational research in GU onc w/ Nima Almassi Chris Weight, Sam Haywood Rebecca Campbell, and the entire team at Cleveland Clinic Urology, with CITI Cleveland Clinic Lerner Research Institute coordination led by Timothy Chan #CancerResearch

🚨 Join us during #ASCO24 🚨 Join Dr. Tian Zhang (@tiansterzhang) on 6/02 for an insightful live In-Person & Virtual #MedEd Symposium at #ASCO24! Explore the latest in #RCC treatment and get expert guidance on navigating state-of-the-art care. KCCure 🔗 bit.ly/2024RCCT

Congratulations Aaron Seo! A well deserved award! Honored to work with you and grateful for your efforts to advance research that is meaningful to #kidneycancer patients.

Thank you Sumanta K. Pal, MD, FASCO for engaging with @kccure and always striving to incorporate the #kidneycancer patient voice in research! I’m sad not to be at ASCO in person this year - but very grateful to you for highlighting this work!

CLEAR trial biomarkers for mRCC. Genomic signatures PBRM BAP1 all do NOT help therapy selection. Lenvatinib and Pembro just worked in all patients better than sunitinib. Complexities of biomarkers highlighted and need to externally validate always. #ASCO24 OncoAlert Toni Choueiri, MD

KIM1 could be a biomarker that can predict DFS and benefit of IO. This was w/ atezo and would be interesting to see what happens in the pembro trial. Important to evaluate in ASSURE or SSIGN nomograms to see if we can improve prediction. Laurence Albiges proud!!! @oncoalert #ASCO24

Beautiful day for a 5k! Loved running with these moms and seeing my daughter reach a new PR! Thanks Munich International School for teaching kids that running is a lifetime sport!

Great recognition for a friend who works every day to deliver best care and teaching experiences. Congrats Suzanne Cole, MD!!

Some important #kidneycancer and #bladdercancer data to look forward to this week! #ESMO24 #ESMOAmbassadors Kidney Cancer KCCure Bladder Cancer Advocacy Network

Does TiVo/nivo close the door on IO post IO? Why was the door ever open? Where is the data supporting continuing IO after failure? For desperate #kidneycancer patients, more always feels better. And far too many oncologists are happy to oblige given the high reimbursement rates

Patients with #papillary and #nonclear #kidneycancer deserve the utmost thanks for participating in these efforts. I would also like to thank groups like KCCure & Kidney Cancer who have brilliant trial-finding tools online! If you are at #ESMO24 & would like to continue this

Huge congrats to Andrea Apolo, M.D. Guru P. Sonpavde, MD Jonathan Rosenberg MD William Y. Kim Stephanie Berg & the Alliance for Clinical Trials in Oncology team on a terrific ESMO - Eur. Oncology presentation & a concomitant NEJM paper! A very exciting #ESMO24 indeed!

Patient Advocacy Lounge at ESMO a great spot to meet with #kidneycancer advocacy colleagues, catch up and check in. Here with Kidney Cancer Dena Battle IKCC Kidney Cancer #ESMO24